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Introduction: Hemoglobin/red cell distribution width (RDW) ratio (HRR) and lymphocyte-to-monocyte ratio (LMR) are two novel bio-
markers associated with overall survival (OS) and prognosis in several types of cancers. The aim of this study is to investigate the value of 
HRR and LMR in newly diagnosed multiple myeloma (MM) patients. Methods: A total of 180 patients were included in this study. Patients 
diagnosed with MM between May 2013 and May 2019 at a single center were evaluated. HRR was calculated by dividing hemoglobin to 
RDW, both measured from the same sample. LMR was calculated by dividing absolute lymphocyte count (ALC) to absolute monocyte 
count (AMC). Results: The cutoff value for HRR was taken as 0.61, and the cutoff value for LMR was taken as 3.28. Patients were divided 
into low HRR, high HRR, low LMR, and high LMR groups. OS of the patients with low HRR was found lower compared with high HRR 
(36.7 months for low HRR and 53.2 months for high HRR, p < 0.001). Also, OS was found lower in the low LMR group (39.4 months for 
low LMR and 51.7 months for high LMR, p = 0.016). On multivariate analysis, low HRR and low LMR were predictive factors of OS (hazard 
ratio (HR) 2.08, 95% confidence intervals (CI) 1.31–3.03, and p = 0.002 for low HRR; HR 1.47, 95% CI 0.92–2.29, and p = 0.010 for low LMR). 
Conclusion: Combining both HRR and LMR could be a prognostic biomarker and it reflects the status of the immune system in newly 
diagnosed MM patients.
©  2020 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo. 
All rights reserved.
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Introduction
Multiple myeloma (MM) is described as a clonal proliferation of malignant 
plasma cells secreting monoclonal immunoglobulin with heavy or light 
chains. This incurable disease is accounted for 1–2% of all cancers 
and 15% of hematological malignancies [1, 2]. Usual presentation and 
end-organ diseases of MM include anemia, hypercalcemia, lytic bone 
lesions, and renal disease.
Anemia itself is accepted as myeloma defining event and is associated 
with involvement of bone marrow of malignant plasma cells [3]. As 
a surrogate of red blood cell size and variability, red cell distribution 
width (RDW) is investigated in several cancer types and associated with 
stage, grade, activity, and prognosis in certain types of cancers [4, 5]. 
Likewise, RDW is demonstrated to be correlated with inflammatory 
states and chronic conditions [6, 7]. Although erythropoiesis can be 
affected by any chronic condition, the variability of RDW, the inclusion 
of hemoglobin levels, and inflammatory markers to the equation might 
bring insight to the pathogenesis of how erythropoiesis is affected and 
the role of bone marrow microenvironment (BME) in MM [8]. Besides, 
RDW itself was proposed as a prognostic factor in symptomatic MM 
patients [9].
As mentioned earlier, BME holds an essential role in the pathogenesis 
of MM. The interactions between BME and malign plasma cells are 
demonstrated to be related to prognosis [10, 11]. These interactions 
cause an immune system to escape due to tumor-associated 
macrophages [12]. The immunosuppressive microenvironment and 
the effect of stromal cell–myeloma cell interferences stimulate the 
expansion of malign plasma cell clone. These immune escape and 
tumor growth are generated by myeloid-derived suppressor cells [13]. 
Peripheral absolute lymphocyte count (ALC) and absolute monocyte 
count (AMC) could preview the balance between the immune system 
and malignancy-associated immune escape. Monocyte count could 
be regarded as myeloid-derived suppressor cells, and therefore the 
ratio of ALC/AMC (LMR) may implicate the effect of the impaired 
immune system on MM [14]. There are studies regarding the effect of 
LMR on overall survival (OS), but combining hemoglobin/RDW ratio 
(HRR) with LMR may reveal the effects of immune dysregulation on 
plasma cell disease [15, 16, 17]. Besides, there is insufficient data 
on the effect of HRR in MM, especially in the era of novel agents. 
Therefore, in this study, we aimed to evaluate the possible impact of 
HRR and LMR on newly diagnosed MM patients treated with novel 
agents as the first line.
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Patients and methods
This retrospective study included 180 patients diagnosed with 
MM according to International Myeloma Working Group (IMWG) 
definitions between May 2013 and May 2019 in Trakya University 
Hematology Department. Baseline demographic features, including 
age and sex, and disease-related data, including heavy and light 
chain types of immunoglobulin, International staging system (ISS), 
whole blood count (WBC), results of the bone marrow sample 
analysis and treatments, were recorded from patient files. WBC was 
performed with Beckman Coulter DXH 800 device, and fresh blood 
samples were obtained after 8 h of fasting and before treatment.
Cytogenetic analysis was performed from bone marrow samples 
obtained at the time of diagnosis and included high-risk determinants 
of MM, such as ISS and revised ISS (R-ISS), according to the 
definitions of IMWG [18, 19]. The ratio of hemoglobin (g/dl) to RDW 
(%) was calculated by the formula hemoglobin/RDW, and LMR was 
calculated by the formula ALC/AMC. Overall survival (OS) was 
accepted as time from date of treatment to date of last follow-up or 
death from any cause.
This study was conducted according to the principles of the Helsinki 
declaration and was approved by the local ethical committee (TUTF-
BAEK 2019-248).
Statistical analysis
IBM Statistical Package for Social Sciences (SPSS) version 20 
was used for statistical analysis. Kolmogorov-Smirnov test was 
performed to assess the distribution of the parameters. Descriptive 
statistics were used to evaluate the characteristics of patients. The 
correlation of HRR and LMR with different variables was assessed 
with Pearson’s chi-squared test or Fisher’s exact test for categorical 
variables and with Mann-Whitney U test for continuous variables. 
The OS is defined as the time from the diagnosis of MM to death from 
any cause. Kaplan-Meier OS estimates were conducted for survival 
analysis. Log-rank test and Cox regression analysis were performed 
to evaluate the estimate hazard ratios (HRs) and 95% confidence 
intervals (CI). A p-value <0.05 was considered to be statistically 
significant. Receiver operating characteristic (ROC) curves and area 
under the curve (AUC) are constructed to define best cutoff values 
for HRR and LMR.
Results
A total of 180 newly diagnosed MM patients were included in this 
study. The mean age of the patients was 66.77 years. Eighty-seven 
patients were male and 93 patients were female. Sixty-eight patients 
were classified as ISS-1, 51 patients were classified as ISS-2, and 
61 patients were classified as ISS-3. Fifty-seven patients (31.6%) 
evaluated were R-ISS-1, 41 (22.8%) patients evaluated were 
R-ISS-2, and 82 (45.6%) patients evaluated were R-ISS-3. Thirty-six 
(20%) patients were regarded as high risk according to the analysis. 
Moreover, in autologous hematopoietic stem cell transplant (ASCT) 
eligible patients, ASCT was performed after 4–6 cycles of induction 
chemotherapy containing bortezomib. Ninety-seven (53.9%) patients 
received bortezomib cyclophosphamide dexamethasone, 8 patients 
(4.4%) received bortezomib thalidomide dexamethasone, 33 patients 
(18.3%) received bortezomib dexamethasone, and 15 patients 
received VTD-PACE (bortezomib, thalidomide, dexamethasone, 
cyclophosphamide, doxorubicin, cisplatin, and etoposide). The 
demographic characteristics of the patients were summarized in 
table I.
The cutoff point for HRR was selected as 0.61 according to ROC 
analysis with an AUC value of 0.64 (95% CI 0.561–0.724). The most 
discriminative value of LMR was also calculated with ROC analysis 
and found to be 3.28 with an AUC value of 0.62 (95% CI 0.538–0.703). 
Patients were categorized as low LMR < 3.28, high LMR > 3.28, 
low HRR < 0.61, and high HRR > 0.61. Patients with low LMR had 
a lower OS compared with patients with high LMR (p = 0.018, HR 
1.67, 95% CI 1.09–2.57), and patients with low HRR had a lower OS 
compared with high HRR (p = 0.001, HR 2.046, 95% CI 1.33–3.13) 
(Kaplan-Meier OS analysis for HRR and LMR was shown in figures 
1 and 2, respectively). Univariate analysis and characteristics of the 
patients according to LMR and HRR were given in tables II and III. 
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Fig. 1. Kaplan-Meier curve for overall survival of low HRR and high HRR
Fig. 2. Kaplan-Meier curve for overall survival of low LMR and high LMR
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Table II. Characteristics of the multiple myeloma patients according to LMR

























































































































Overall survival months 39.44 ± 3.72 51.79 ± 3.68 0.016
Univariate analysis for low LMR, HR: 1.67 (95% CI 1.09–2.57)
On multivariate analysis, low HRR and low LMR are associated with 
lower OS (HR for HRR 2.08, 95% CI 1.31–3.03, p = 0.002; and HR 
for low LMR 1.47, 95% CI 0.92–2.29, p = 0.010). Also ASCT, high-
risk MM, and ISS-3 were associated with lower OS on multivariate 
analysis (details of the multivariate cox-regression analysis was 
given in table. IV). Furthermore, we have stratified our patients into 
four groups: low LMR and low HRR, low LMR and high HRR, high 
LMR and low HRR, and high LMR and high HRR. The OS of these 
four groups was 34.6, 44.8, 40.5, and 56.1 months, respectively. OS 
was lower in the low LMR and low HRR groups, which was higher in 
high LMR and high HRR groups.
Discussion
MM is an incurable disease with complex biological heterogeneity. 
The underlying complex biology plays a unique role in the clinical 
course and prognosis of the disease. In this study, baseline WBC 
parameters were analyzed for their probable role in the OS of MM 
patients. These findings underline that no matter how complicated 
diseases and treatments become in the real world, simple laboratory 
tests such as complete blood count will always be valuable. In this 
regard, both HRR and LMR have been associated with prognosis 
in several types of cancers [4, 20]. In two recent analyses, HRR is 
suggested as a prognostic factor for survival in both non-small cell 
lung cancer and head and neck cancer [21, 22].
Anemia itself is a common phenomenon in cancer patients and is 
caused by several mechanisms. An association with anemia and 
prognosis is demonstrated in several types of solid and hematological 
malignancies [23, 24]. Development of anemia in MM is caused by 
the infiltration of malign plasma cells in the bone marrow, which 
results in suppressing erythropoiesis and dysregulated apoptosis 
of plasma cells [3, 25]. However, stromal and endothelial cells in 
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Table III. Characteristics of the multiple myeloma patients according to HRR

























































































































Overall survival months 36.70 ± 3.77 53.32 ± 3.54 0.001
Univariate analysis for low HRR, HR; 2.046 (95% CI 1.33–3.13)
Table IV. Multivariate analysis for overall survival
Multivariate analysis
Hazard ratio (HR) 95% CI p-value
LMR < 3.28 1.47 0.92–2.29 0.010
HRR < 0.61 2.08 1.31–3.03 0.002
Gender 0.74 0.47–1.14 0.178
Age 0.99 0.97–1.02 0.782
No ASCT versus ASCT 0.14 0.07–0.27 0.000
High risk MM 0.35 0.21–0.59 0.000
ISS 1.89 1.09–3.30 0.023
Revised ISS 0.79 0.35–1.19 0.008
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bone marrow contribute to the development of anemia by producing 
specific cytokines, particularly interleukin 6 (IL-6) [8]. Likewise, 
renal insufficiency also contributes to the development of anemia 
in MM patients via erythropoietin deficiency [26]. Furthermore, the 
interaction of plasma cells with the tumor microenvironment might 
play a role in the progression of the disease and the worsening of 
anemia [11].
Indeed, RDW itself is a reliable marker of red cell size variability. 
Several relations with RDW and age-related clonal hematopoiesis 
were reported. Even high RDW was associated with the risk of 
acute myeloid leukemia development in healthy individuals [27]. 
Besides, there was an association of increased RDW with worse OS 
in myelodysplastic syndrome (MDS) patients, especially in patients 
with refractory anemia [28]. This observation might be regarded 
as the effects of dysregulated erythropoiesis on RDW in MDS [28]. 
RDW is also associated with several types of solid and hematological 
malignancies [4, 29]. For example, in a recent analysis, high RDW 
was associated with lower progression-free survival and OS in MM 
[30]. A retrospective analysis including 161 patients with diffuse 
large B cell lymphoma evaluated the relationship of RDW with 
OS [31]. The authors reported that high RDW was associated 
with lower progression-free survival and OS [31]. Considering the 
high incidence of anemia in solid and hematological cancers, it is 
noteworthy that high RDW was associated with lower survival in 
several hematological malignancies. Therefore, HRR is thought to be 
a logical and surrogate prognostic marker. However, data including 
HRR in hematological malignancies are scarce. Several studies 
including data of real-world patients are needed in hematological 
cancers, especially in MM. Although hemoglobin or RDW alone has 
been shown to have an impact on prognosis in MM patients, we have 
shown that HRR may affect OS and prognosis alone. Considering that 
both low hemoglobin and high RDW have an impact on prognosis, 
it will not be difficult and surprising to predict that HRR may also 
affect prognosis. However, multivariate analysis showed that HRR is 
associated with poor prognosis compared with high HRR. A second 
important issue is that both hemoglobin and RDW might be affected 
by nutritional deficiencies besides the effect of MM infiltration and 
cytokines. In this case, HRR can be suggested as a more powerful 
and reliable marker.
The BME holds a critical role, especially in the progress of MM 
[10]. The interactions in malign plasma cells with BME cause an 
immunosuppressive state and may result in an immune escape 
causing myeloma cell growth [11, 13]. These interplays stimulate 
several regulatory or inhibitory cells. Various suggestions have been 
made to measure and show the contribution of immunosuppression 
induced by tumor microenvironment [13, 32]. It has been shown 
that both ALC and AMC could be an indirect indicator of immune 
surveillance. Thus, LMR, which is obtained by dividing ALC by 
AMC, could also be an additional determiner [12, 16]. Several 
studies investigated the effect of LMR in MM. The prognostic 
value of ALC, AMC, and LMR was analyzed in 189 MM patients 
retrospectively [17]. In multivariate analysis, low LMR was an 
independent poor prognostic factor. Low LMR is reported to be 
<2.9 in this study. In another retrospective analysis, the authors 
stated that peripheral blood monocyte count could be correlated 
with tumor-associated macrophages, thus reflecting immune status 
[16]. This study included 372 newly diagnosed MM patients and 
cutoff value for LMR was determined as 3.6. Low LMR is associated 
with lower progression-free survival and OS on multivariate analysis 
[16]. Another study questioned the value of LMR evaluated in 
285 MM patients [33]. In this study, the cutoff for LMR was 4.2, and 
low LMR is found to be an independent factor for OS [33]. These 
studies indicated the value of LMR in MM patients. In our study, 
fewer patients in the low LMR group proceeded to the ASCT, which 
may be the explanation for lower OS in the low LMR group. As we 
mentioned earlier, the search for a basic and reliable marker for 
immune regulation and prognosis is mandatory. The main limitation 
of the studies involving LMR is that lymphocyte and monocyte counts 
can be affected by a variety of reasons that do not affect the disease, 
mainly infections. In addition, different cutoff values are taken for 
LMR in different studies. This situation is also a confounding factor. 
Therefore, we consider that the combination of LMR and HRR might 
partially overcome these limitations.
Although medicine is becoming more and more complicated every 
day, simple, easily accessible, and useful markers are required to 
predict the prognosis of malignant diseases, especially in developing 
countries. In this study, we found that two complete blood count 
parameters that can be easily obtained, such as HRR and LMR, 
might be independent factors in predicting prognosis in MM patients.
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